« Back to report listing

OVERVIEW

Cost:$1500

PUBLICATION DATE:August 2010

THERAPEUTIC CLASS:Oncology

Number of Pages:99

standard report icon

US Renal Cell Carcinoma

Competitive Market Analysis &
Forecast 2010-2013

REPORT SUMMARY

With a growth rate of 5% per year in market size, Renal Cell Carcinoma treatments are likely to have many changes in market share throughout the forecast period of 2010-2013. Although few new players are likely to enter the market, market share will vary with an increased diagnosis rate as well as treatment effectiveness measures. PharmaPeek’s report provides a close examination of the market in its entirety.


EXECUTIVE SUMMARY

Each year, over 50,000 people in the United States are diagnosed with renal cell carcinoma. Of these diagnoses, most occur in people aged 50-70 years, but the disease can occur at any age. About twice as many men as women develop this cancer, and it occurs in all races and ethnic groups. Further, approximately 1300 people died of renal cell carcinoma in 2009.

In 2009, the US renal cell carcinoma market was estimated to be worth $467 million. The market is forecasted to grow at a cumulative annual growth rate (CAGR) of 5.0 percent over the forecast period. By the end of the forecast period, 2013, the market is estimated to generate $565 million in revenues.

The treatment of metastatic renal cell carcinoma (RCC), a highly vascularized disease, has changed dramatically during the past few years. Previously, RCC had been considered a malignancy that was refractory to most therapies, including chemotherapy and immunotherapy, however, the improved understanding of the biology of RCC has resulted in the development of novel agents that target important pathways involved in angiogenesis and tumor growth. In particular, the vascular endothelial growth factor (VEGF) pathway and the mammalian target of rapamycin (mTOR) signal transduction pathway have been used to date.

Agents that target the VEGF pathway are responsible for the largest portion of the RCC market. There are many drugs with novel mechanism of action (MOA) currently in various phases of development. Some of the promising classes are integrins inhibitors, c-MET inhibitors, DAC inhibitors, among many others. There are also several agents in the pipeline targeting the VEGF pathway. Oncology agents approved for other indications besides RCC, may also enter the RCC market within the forecast period.

Targeted therapy, focusing on VEGF, will continue to control the market through the forecast period, 2013. However, a new agent, Axitinib by Pfizer, is likely to enter the market in 2011, followed by another agent in early trials near the end of the forecast period. This market will grow steadily as people are diagnosed with kidney cancer earlier and patients are living longer due to effective treatments. Further, the market share of the individual therapies will change throughout the forecast period, however the players will change very little, with only 1 to 2 new agents appearing on the market in this forecast period.


TABLE OF CONTENTS

  • Chapter 1: Introduction to Renal Cell Cancer
    • RCC Subtypes
  • Chapter 2: RCC Industry Activity Overview
    • Epidemiology-Statistics
    • Risk Factors
    • Diagnosis
    • Staging
    • Competitors
  • Chapter 3: Renal Cell Carcinoma Market Analysis
    • Key Drivers for the RCC Market
    • Key Challenges for the RCC Market
  • Chapter 4: Individual Competitor Overview
    • Immunotherapy
    • Targeted Therapies
  • Chapter 5: Pipeline
    • Late Phase
    • Early Phase; Drugs in Development Phase I or II (RCC Specific), 2009
    • Very Early Phase (Investigational Clinical Trials)
    • Immunostimulatory
  • Chapter 6: Sequencing and Combination Therapies
    • Sequencing Therapies
    • Combination Therapies
  • Chapter 7: Biomarkers
    • VHL Inactivation
    • Carbonic Anhydrase IX
    • VEGF
    • Current Clinical Trial Investigating Potential Biomarkers
  • Chapter 8: RCC Summary
    • Future Revenue Projections

COMPANIES DISCUSSED

  • Schering
  • Roche
  • Bayer
  • Onyx
  • Pfizer
  • Wyeth
  • Novartis
  • GSK
  • Antigenics
  • AstraZeneca
  • Abbott
  • Chiron
  • Aveo
  • Novartis-Shering
  • Facet Biotech
  • MedImmune
  • Centocor
  • CovX
  • Amgen
  • Regeneron
  • ImClone
  • Keryx
  • BMS
  • OSI
  • Chephalon
  • Exelexis
  • UCB Group
  • PTC Therapeutics
  • Introgen
  • Merck
  • Eisal
  • ArQule
  • SuperGen
  • BioMedica.

DRUGS DISCUSSED

  • Proleukin (IL-2)
  • INTRON*A
  • Roferon*-A
  • Nexavar
  • Sutent
  • Temsirolimus
  • Everolimus
  • Votrient
  • Avastin
  • Sorafenib
  • Sunitinib
  • Temsirolimus
  • Everolimus
  • Bevacizumab
  • Pazopanib
  • Vinblastine
  • Floxuridine
  • 5-FU
  • Capecitabine
  • Gemcitabine
  • Oncophage
  • IFN (Interferon-Alfa)
  • Axitinib
  • Recentin
  • Vandetanib
  • DAST
  • Linifanib
  • CHIR-258
  • GSK089
  • AV-951
  • Vatalanib
  • Volociximab
  • Vitaxin
  • CNT-095
  • CVX-060
  • AMG-386
  • Aflibercept
  • IMC-1121B
  • Perifosine
  • Panobinostat
  • AMG 102
  • Motesanib
  • Telatinib
  • Angiocept
  • OSI-930
  • CEP-11981
  • XL820
  • XL647
  • CDP791
  • PTC299
  • INGN 241
  • Cilengitide
  • E7820
  • CP-868
  • 596
  • XL184
  • ARQ-197
  • PF2341066
  • MP-470
  • Trovax
  • CTLA-4.